TGFβ stimulation in ovarian cancer cells treated with non-specific DNMT inhibitor SGI-110 or guadecitabine led to increased activity and nuclear localization of particularly DNMT1 and prevention of CDH1 silencing, which suggests a TGFβ-DNMT1-CDH1 pathway. Here, DNMT1 is linked to ovarian carcinoma.